Side-by-side · Research reference
P21vsRetatrutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED8/36 cited
BPhase 2HUMAN-REVIEWED10/41 cited
P21
CNTF-Derived Neuropeptide · Animal Model Evidence
Animal onlyEvidence level
SQ · Site unspecified · Frequency unknown
Retatrutide
Triple-receptor agonist · Phase 3
SQ · Abdomen · Once weekly
01Mechanism of Action
Parameter
P21
Retatrutide
Primary target
CNTF receptor alpha (CNTFRα) / LIF receptor (LIFR) / gp130 complex on neural stem cells
GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023
Pathway
CNTF mimetic → CNTFRα/LIFR/gp130 heterotrimer → JAK/STAT3 signaling → neurogenesis, stem cell proliferation, neuroprotection
Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)Jastreboff 2023
Downstream effect
Increased neural stem cell self-renewal, globose basal cell activation (Mash1+ cells), olfactory sensory neuron regeneration, hippocampal neurogenesis, neuroprotection in developmental disorders
Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP aloneJastreboff 2023
Feedback intact?
—
—
Origin
Small-molecule peptide mimetic derived from full-length ciliary neurotrophic factor (CNTF), designed to retain receptor activation with improved pharmacokineticsMottolese 2024
Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptorsJastreboff 2023
Antibody development
—
—
02Dosage Protocols
Parameter
P21
Retatrutide
Human dosing
No established protocol
No clinical trial data available.
—
Animal models (mice)
Dose and route not specified in abstractsMottolese 2024Jia 2020
In vitro and in vivo studies demonstrate efficacy; precise dosing protocols not disclosed.
—
Evidence basis
Animal models only
CDKL5 KO mice, methimazole-induced olfactory injury, CNTF-/- knockout models.Mottolese 2024Cox 2026Jia 2020
Phase 2 trial; Phase 3 ongoingJastreboff 2023
Duration
Not specified
Indefinite for chronic indication (presumed)
Route
Presumed subcutaneous or intraperitoneal (animal studies)
—
Frequency
—
Once weekly
Titration schedule
—
2 mg → 4 mg → 8 mg → 12 mg over 16 weeks
Reconstitution
—
Investigational; not commercially available
Timing
—
Any time of day
Half-life
—
~6 days (estimated from class)
04Side Effects & Safety
Parameter
P21
Retatrutide
Human safety data
None available
No clinical trials in humans.
—
Animal tolerability
Well-tolerated in mouse models; no toxicity reported in available abstracts
—
Theoretical risks
Uncontrolled stem cell proliferation, immune response to peptide, unknown long-term CNS effects
—
Glucose handling
—
Glycemic improvement; rare hyperglycemia from glucagon component
Pancreatitis risk
—
Class warning
Thyroid C-cell tumours
—
Class warning (presumed)
Pregnancy / OB
—
Avoid (insufficient data)
Absolute Contraindications
P21
- ·Use in humans not validated
Retatrutide
- ·MTC personal or family history (presumed class effect)
- ·Pregnancy / breastfeeding
Relative Contraindications
P21
- ·Active malignancy (theoretical — neurotrophic signaling may affect tumour growth)
- ·Pregnancy or lactation (no safety data)
Retatrutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe cardiovascular disease (HR signal)
05Administration Protocol
Parameter
P21
Retatrutide
1. Human protocol
Not established. No FDA approval, no clinical trial data.
Investigational peptide. Research vials reconstituted with bacteriostatic water per label.
2. Animal research context
In vivo studies used systemic administration (route not specified in abstracts) in mouse models of neurodegeneration, olfactory injury, and CDKL5 deficiency disorder. In vitro studies used primary cell cultures.
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
—
Once weekly, same day.
4. Storage
—
Refrigerate 2–8 °C. Light-protected.
5. Needle
—
27–31G, 4–8 mm insulin syringe.